Journal article · 2025 · Open access

Neue Erkenntnisse aus dem RABBIT-Register zum Krebsrisiko von Patient:innen mit rheumatoider Arthritis bei Therapie mit Januskinaseinhibitoren

Martin Schäfer, Anja Strangfeld

Zeitschrift für Rheumatologie, 85(1), 65–69 · Published 20 October 2025 · DOI 10.1007/s00393-025-01740-x

Open PDFView at the publisherCite this paper

In brief

“Neue Erkenntnisse aus dem RABBIT-Register zum Krebsrisiko von Patient:innen mit rheumatoider Arthritis bei Therapie mit Januskinaseinhibitoren” is a 2025 journal article by Martin Schäfer and Anja Strangfeld, published in Zeitschrift für Rheumatologie. OpenAlex counts 1 citations as of 19 November 2026, which puts it in the top 9% of works published in 2025 by citations. It is open access under a CC BY licence: the full text is free to read at Zeitschrift für Rheumatologie.

Citations
1
Most cited in
2026 (1)
Field-weighted impact
0.52
References
9
Authors
2

Abstract

Janus kinase inhibitors (JAKis) are highly effective drugs for treating inflammatory rheumatic diseases. The randomized ORAL surveillance trial showed that patients with rheumatoid arthritis (RA) aged 50 years and older with at least 1 more cardiovascular risk factor had an increased risk of malignant diseases with the JAKi tofacitinib compared to tumor necrosis factor inhibitors; however, this result has not been replicated in subsequent studies. An analysis of the German RABBIT register now revealed an overall slightly increased cancer risk in RA patients ever treated with JAKi compared to those ever treated with biological (b) disease-modifying antirheumatic drugs (DMARDs). During or after 2285 JAKi treatment episodes and 4259 bDMARD treatment episodes, 88 and 135 malignant diseases occurred, respectively, resulting in a rate of 11.6 (95% confidence interval, CI: 9.3-14.3) events for JAKis and 8.9 (95% CI: 7.4-10.5) events for bDMARDs per 1000 patient years. The adjusted hazard ratio was 1.40 (95% CI: 1.09-1.80), which is comparable to the results from the ORAL surveillance study. Particularly affected by the observed risk increase were patients aged 60 years and older, those with high disease activity and those who had already received ≥ 3 treatments with conventional synthetic DMARDs. Other above-average affected groups included smokers, male patients and patients with an RA duration of > 10 years. When treating patients with an increased risk, clinicians should carefully consider together with them whether this observed risk outweighs the potential risks of discontinuing or withholding a highly effective treatment such as JAKis, bearing in mind that inadequate disease control is also associated with an increased risk of cancer. When in doubt, the results from RABBIT should not discourage physicians from prescribing a JAKi treatment to patients who need it. It could be a way forward to ensure that a close cancer screening is carried out for risk patients treated with JAKis.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Schäfer, M., & Strangfeld, A. (2025). Neue Erkenntnisse aus dem RABBIT-Register zum Krebsrisiko von Patient:innen mit rheumatoider Arthritis bei Therapie mit Januskinaseinhibitoren. Zeitschrift für Rheumatologie, 85(1), 65–69. https://doi.org/10.1007/s00393-025-01740-x

MLA 9

Schäfer, Martin, and Anja Strangfeld. “Neue Erkenntnisse aus dem RABBIT-Register zum Krebsrisiko von Patient:innen mit rheumatoider Arthritis bei Therapie mit Januskinaseinhibitoren.” Zeitschrift für Rheumatologie, vol. 85, no. 1, 2025, pp. 65–69. https://doi.org/10.1007/s00393-025-01740-x.

Chicago

Schäfer, Martin and Anja Strangfeld. 2025. “Neue Erkenntnisse aus dem RABBIT-Register zum Krebsrisiko von Patient:innen mit rheumatoider Arthritis bei Therapie mit Januskinaseinhibitoren.” Zeitschrift für Rheumatologie 85 (1): 65–69. https://doi.org/10.1007/s00393-025-01740-x.

Harvard

Schäfer, M. and Strangfeld, A. (2025) ‘Neue Erkenntnisse aus dem RABBIT-Register zum Krebsrisiko von Patient:innen mit rheumatoider Arthritis bei Therapie mit Januskinaseinhibitoren’, Zeitschrift für Rheumatologie, 85(1), pp. 65–69. doi:10.1007/s00393-025-01740-x.

IEEE

M. Schäfer and A. Strangfeld, “Neue Erkenntnisse aus dem RABBIT-Register zum Krebsrisiko von Patient:innen mit rheumatoider Arthritis bei Therapie mit Januskinaseinhibitoren,” Zeitschrift für Rheumatologie, vol. 85, no. 1, pp. 65–69, 2025, doi: 10.1007/s00393-025-01740-x.

BibTeX

@article{schafer2025neue,
  title     = {{Neue Erkenntnisse aus dem RABBIT-Register zum Krebsrisiko von Patient:innen mit rheumatoider Arthritis bei Therapie mit Januskinaseinhibitoren}},
  author    = {Schäfer, Martin and Strangfeld, Anja},
  journal   = {Zeitschrift für Rheumatologie},
  year      = {2025},
  volume    = {85},
  number    = {1},
  pages     = {65--69},
  doi       = {10.1007/s00393-025-01740-x},
  url       = {https://doi.org/10.1007/s00393-025-01740-x}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies

  • rheumatoid arthritis
  • JAK inhibitors
  • tofacitinib
  • cancer risk
  • biologic DMARDs
  • disease-modifying antirheumatic drugs
  • risk-benefit assessment
  • cancer screening

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Schäfer, M., & Strangfeld, A. (2025). Neue Erkenntnisse aus dem RABBIT-Register zum Krebsrisiko von Patient:innen mit rheumatoider Arthritis bei Therapie mit Januskinaseinhibitoren. Zeitschrift für Rheumatologie, 85(1), 65–69. https://doi.org/10.1007/s00393-025-01740-x

How many times has this paper been cited?

1 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Zeitschrift für Rheumatologie: sign in and open the PDF from this page.

Who wrote this paper?

Martin Schäfer, Anja Strangfeld.

What is the DOI of this paper?

10.1007/s00393-025-01740-x, permanently at https://doi.org/10.1007/s00393-025-01740-x. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.